Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct in Patients With End-Stage Liver Disease Under Consideration for Liver Transplant.

NCT04089969 is registered in ClinicalTrials.gov with Corewell Health East as lead sponsor.

NCT NCT04089969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04089969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct in Patients With End-Stage Liver Disease Under Consideration for Liver Transplant.
Lead sponsor
Corewell Health East
Phase
Not applicable
Overall status
Withdrawn
Start date
June 30, 2023
Completion date
June 30, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute liver failure, coronary artery disease, liver transplant